Europe’s Troubling Shift and America’s Stance on Life
There’s a tendency among some elites to idealize Europe, often highlighting its universal healthcare, shorter work weeks, and sophisticated culture. However, what’s not often discussed is something quite stark: the growing trend of assisted suicide across the continent.
Many Western European nations have started to legalize aid in dying. Recent news from the UK has spotlighted this issue, but similar laws are already in effect in countries like Austria, Belgium, Luxembourg, and Spain. Meanwhile, Switzerland offers its own version through a so-called “suicide pod.” Both Belgium and the Netherlands have allowed euthanasia since 2002, and statistics are revealing. In Belgium, euthanasia cases surpassed 3,400 in 2023, reflecting a 15% increase from the previous year. The Netherlands recorded over 9,000 cases, marking an 87% rise since 2013.
What’s concerning is that these cases aren’t just affecting the elderly or those with terminal illnesses. For instance, younger individuals in the Netherlands are also utilizing state assistance for suicide based on mental health struggles. It seems as if there’s a pervasive sense of hopelessness in Western Europe.
In stark contrast, the United States is firmly focused on the values of life, liberty, and the pursuit of opportunities. The narrative here leans towards rejecting the idea of a right to die, perhaps favoring the right to strive for life.
Back in May 2018, former President Trump signed legislation enabling those with terminal diagnoses to access experimental drugs that passed initial testing, despite not yet being approved by the FDA. While traditional drug approval processes are stringent, this initiative allows alternative routes for individuals who might not have other options.
Interestingly, although the majority of Democrats opposed this legislation aimed at preserving life, 41 states have successfully enacted their own variations of a law first introduced in Colorado back in 2014.
Additionally, during his second term, Trump initiated a drive to enhance American biotechnology, emphasizing the need for the U.S. to lead globally in drug development. In recent years, the U.S. has been at the forefront of creating more new prescription medications than the rest of the world combined.
Maintaining this leadership is critical, especially given China’s rapid advancement in clinical trials and drug approvals. Between 2017 and 2023, China’s participation in clinical trials surged by 300%, placing it third globally. The U.S. cannot afford to lose its biotechnology prowess to a nation that exports dangerous substances while embracing state-sponsored healthcare models that might undermine individual choice.
Concerns about price management are widespread, both in the short and long term. Political figures like Joe Biden and Bernie Sanders have shown support for European-style drug pricing models, which could stifle innovation and ultimately harm future treatment options.
Trump has taken a stand to ensure that European nations contribute their fair share toward the cost of American drug innovations, similar to how they are expected to spend on NATO defense. His strategy aims to provide U.S. patients with access to advanced drugs while making prices more manageable at home.
It’s essential for America to safeguard its right to pursue beneficial health innovations without importing problematic ideologies from abroad. The sentiment is clear: life is valued differently in Europe, and importing unsuccessful policies is not the answer. By prioritizing the acceleration of American biotechnology, benefits are likely to reach both Americans and the global community.
While Europe may explore avenues like suicide pods, under past leadership, the U.S. has focused on cultivating groundbreaking pharmaceutical advancements that could change lives in the 21st century.
